Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study

2004 Goldman, 1982, Marrow transplantation for patients in the chronic phase of chronic granulocytic leukaemia, Lancet, 2, 623, 10.1016/S0140-6736(82)92736-2 Storb, 1985, Graft-versus-host disease in dog and man: the Seattle experience, Immunol Rev, 88, 215, 10.1111/j.1600-065X.1985.tb01160.x Ringden, 1985, Death by graft-versus-host disease associated with HLA mismatch, high recipient age, low marrow cell dose, and splenectomy, Transplantation, 40, 39, 10.1097/00007890-198507000-00009 Deeg, 2007, How I treat refractory acute GVHD, Blood, 109, 4119, 10.1182/blood-2006-12-041889 Friedenstein, 1968, Heterotopic of bone marrow: analysis of precursor cells for osteogenic and hematopoietic tissues, Transplantation, 6, 230, 10.1097/00007890-196803000-00009 Haynesworth, 1992, Characterization of cells with osteogenic potential from human marrow, Bone, 13, 81, 10.1016/8756-3282(92)90364-3 Noort, 2002, Mesenchymal stem cells promote engraftment of human umbilical cord blood-derived CD34(+) cells in NOD/SCID mice, Exp Hematol, 30, 870, 10.1016/S0301-472X(02)00820-2 Klyushnenkova, 2005, T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression, J Biomed Sci, 12, 47, 10.1007/s11373-004-8183-7 Le Blanc, 2003, Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex, Scand J Immunol, 57, 11, 10.1046/j.1365-3083.2003.01176.x Bartholomew, 2002, Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo, Exp Hematol, 30, 42, 10.1016/S0301-472X(01)00769-X Ortiz, 2003, Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects, Proc Natl Acad Sci USA, 100, 8407, 10.1073/pnas.1432929100 Togel, 2005, Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms, Am J Physiol Renal Physiol, 289, F31, 10.1152/ajprenal.00007.2005 Zappia, 2005, Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy, Blood, 106, 1755, 10.1182/blood-2005-04-1496 Horwitz, 2002, Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: implications for cell therapy of bone, Proc Natl Acad Sci USA, 99, 8932, 10.1073/pnas.132252399 Lazarus, 1995, Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use, Bone Marrow Transplant, 16, 557 Lazarus, 2005, Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients, Biol Blood Marrow Transplant, 11, 389, 10.1016/j.bbmt.2005.02.001 Koc, 2000, Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy, J Clin Oncol, 18, 307, 10.1200/JCO.2000.18.2.307 Ball, 2007, Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation, Blood, 110, 2764, 10.1182/blood-2007-04-087056 Le Blanc, 2007, Transplantation of mesenchymal stem cells to enhance engraftment of hematopoietic stem cells, Leukemia, 21, 1733, 10.1038/sj.leu.2404777 Le Blanc, 2004, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells, Lancet, 363, 1439, 10.1016/S0140-6736(04)16104-7 Ringden, 2006, Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease, Transplantation, 81, 1390, 10.1097/01.tp.0000214462.63943.14 Glucksberg, 1974, Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors, Transplantation, 18, 295, 10.1097/00007890-197410000-00001 Horwitz, 2005, Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement, Cytotherapy, 7, 393, 10.1080/14653240500319234 Gooley, 1999, Estimation of failure probabilities in the presence of competing risks: new representations of old estimators, Stat Med, 18, 695, 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O Fine, 1999, Proportional hazard model for the sub-distribution of competing risks, J Amer Stat Assoc, 94, 496, 10.1080/01621459.1999.10474144 Remberger, 2001, Treatment of severe acute graft-versus-host disease with anti-thymocyte globulin, Clin Transplant, 15, 147, 10.1034/j.1399-0012.2001.150301.x Aggarwal, 2005, Human mesenchymal stem cells modulate allogeneic immune cell responses, Blood, 105, 1815, 10.1182/blood-2004-04-1559 Le Blanc, 2005, Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 321, 10.1016/j.bbmt.2005.01.005 Meisel, 2004, Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation, Blood, 103, 4619, 10.1182/blood-2003-11-3909